News
AIM
9.08
-0.71%
-0.07
Weekly Report: what happened at AIM last week (0707-0711)?
Weekly Report · 1d ago
Weekly Report: what happened at AIM last week (0630-0704)?
Weekly Report · 07/07 10:15
AIM ImmunoTech presents on potential of private-public partnerships for oncology
TipRanks · 07/02 13:00
Weekly Report: what happened at AIM last week (0623-0627)?
Weekly Report · 06/30 10:18
Weekly Report: what happened at AIM last week (0616-0620)?
Weekly Report · 06/23 10:15
AIM ImmunoTech Faces NYSE Noncompliance Notification
TipRanks · 06/20 21:19
AIM ImmunoTech receives noncompliance notification from NYSE
TipRanks · 06/20 20:30
AIM ImmunoTech Announces NYSE American Notice of Noncompliance With Minimum Stockholders’ Equity Requirements
Barchart · 06/20 15:15
*News On AIM ImmunoTech Inc. (AIMID) Now Under AIM
Dow Jones · 06/17 21:08
AIM ImmunoTech Inc. Common Stock Resumes Trading on NYSE American
NASDAQ · 06/17 13:00
Weekly Report: what happened at AIMID last week (0609-0613)?
Weekly Report · 06/16 10:18
AIM ImmunoTech announces 1-for-100 reverse stock split
Seeking Alpha · 06/11 20:19
Weekly Report: what happened at AIMI last week (0602-0606)?
Weekly Report · 06/09 10:19
Weekly Report: what happened at AIMI last week (0526-0530)?
Weekly Report · 06/02 10:24
Weekly Report: what happened at AIMI last week (0519-0523)?
Weekly Report · 05/26 10:23
Weekly Report: what happened at AIMI last week (0512-0516)?
Weekly Report · 05/19 10:18
Based on the provided financial report articles, I generated the title for the article: "AIM ImmunoTech Inc. (0000946644) Quarterly Report (Q1 2025)" Please note that the title may not be exact, as the provided text does not contain a clear title. However, based on the information provided, I inferred the title to be related to AIM ImmunoTech Inc.'s quarterly report for the first quarter of 2025.
Press release · 05/17 05:45
Weekly Report: what happened at AIMI last week (0505-0509)?
Weekly Report · 05/12 10:19
AIM ImmunoTech Announces the Presentation of Ampligen Oncology Data at the Recent Annual Meeting of the American Association of Immunologists
Barchart · 05/08 07:45
Weekly Report: what happened at AIMI last week (0428-0502)?
Weekly Report · 05/05 10:19
More
Webull provides a variety of real-time AIM stock news. You can receive the latest news about Aim Immunotech through multiple platforms. This information may help you make smarter investment decisions.
About AIM
AIM ImmunoTech Inc. is an immuno-pharma company. The Company is focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders and viral diseases, including COVID-19. The Company’s flagship products are Ampligen (rintatolimod) and Alferon N Injection (Interferon alfa). Ampligen is a double-stranded RNA (dsRNA) and highly selective TLR3 agonist immuno-modulator, which is being developed for globally important cancers, viral diseases and disorders of the immune system. Ampligen is approved for commercial sale in the Argentine Republic for the treatment of severe chronic fatigue syndrome (CFS). Alferon N Injection is an injectable formulation of natural alpha interferon, which is approved for sale in the United States and Argentina for the intralesional treatment of refractory or recurring external genital warts in patients 18 years of age or older.